These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
444 related items for PubMed ID: 8551879
1. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Bouhnik Y, Lémann M, Mary JY, Scemama G, Taï R, Matuchansky C, Modigliani R, Rambaud JC. Lancet; 1996 Jan 27; 347(8996):215-9. PubMed ID: 8551879 [Abstract] [Full Text] [Related]
2. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Kim PS, Zlatanic J, Korelitz BI, Gleim GW. Am J Gastroenterol; 1999 Nov 27; 94(11):3254-7. PubMed ID: 10566725 [Abstract] [Full Text] [Related]
3. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Prefontaine E, Macdonald JK, Sutherland LR. Cochrane Database Syst Rev; 2009 Oct 07; (4):CD000545. PubMed ID: 19821270 [Abstract] [Full Text] [Related]
4. [Optimization of immunomodulatory treatment with azathioprine or 6-mercaptopurine in inflammatory bowel disease]. Bastida Paz G, Nos Mateu P, Aguas Peris M, Beltrán Niclós B, Rodríguez Soler M, Ponce García J. Gastroenterol Hepatol; 2007 Nov 07; 30(9):511-6. PubMed ID: 17980127 [Abstract] [Full Text] [Related]
5. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Prefontaine E, Macdonald JK, Sutherland LR. Cochrane Database Syst Rev; 2010 Jun 16; (6):CD000545. PubMed ID: 20556747 [Abstract] [Full Text] [Related]
6. Predictive factors of response of perianal Crohn's disease to azathioprine or 6-mercaptopurine. Lecomte T, Contou JF, Beaugerie L, Carbonnel F, Cattan S, Gendre JP, Cosnes J. Dis Colon Rectum; 2003 Nov 16; 46(11):1469-75. PubMed ID: 14605564 [Abstract] [Full Text] [Related]
7. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy. Nørgård BM. Dan Med Bull; 2011 Dec 16; 58(12):B4360. PubMed ID: 22142578 [Abstract] [Full Text] [Related]
8. Methotrexate for induction of remission in refractory Crohn's disease. McDonald JW, Tsoulis DJ, Macdonald JK, Feagan BG. Cochrane Database Syst Rev; 2012 Dec 12; 12():CD003459. PubMed ID: 23235598 [Abstract] [Full Text] [Related]
9. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Cochrane Database Syst Rev; 2009 Jan 21; (1):CD000067. PubMed ID: 19160175 [Abstract] [Full Text] [Related]
10. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. Ramakrishna J, Langhans N, Calenda K, Grand RJ, Verhave M. J Pediatr Gastroenterol Nutr; 1996 Apr 21; 22(3):296-302. PubMed ID: 8708884 [Abstract] [Full Text] [Related]
11. Outcome predictors for thiopurine maintenance therapy in patients with Crohn's disease. Park JJ, Cheon JH, Hong SP, Kim TI, Kim WH. Dig Dis Sci; 2012 Jan 21; 57(1):133-41. PubMed ID: 22057283 [Abstract] [Full Text] [Related]
12. Long-term immunosuppressive treatment in Crohn's disease. Nyman M, Hansson I, Eriksson S. Scand J Gastroenterol; 1985 Dec 21; 20(10):1197-203. PubMed ID: 3912958 [Abstract] [Full Text] [Related]
13. Routine use of thiopurines in maintaining remission in pediatric Crohn's disease. Boyle BM, Kappelman MD, Colletti RB, Baldassano RN, Milov DE, Crandall WV. World J Gastroenterol; 2014 Jul 21; 20(27):9185-90. PubMed ID: 25083093 [Abstract] [Full Text] [Related]
14. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice. Ampuero J, Rojas-Feria M, Castro-Fernández M, Millán-Lorenzo M, Guerrero-Jiménez P, Romero-Gómez M. J Gastroenterol Hepatol; 2016 Jan 21; 31(1):112-8. PubMed ID: 26173493 [Abstract] [Full Text] [Related]
15. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Kennedy NA, Kalla R, Warner B, Gambles CJ, Musy R, Reynolds S, Dattani R, Nayee H, Felwick R, Harris R, Marriott S, Senanayake SM, Lamb CA, Al-Hilou H, Gaya DR, Irving PM, Mansfield J, Parkes M, Ahmad T, Cummings JR, Arnott ID, Satsangi J, Lobo AJ, Smith M, Lindsay JO, Lees CW. Aliment Pharmacol Ther; 2014 Dec 21; 40(11-12):1313-23. PubMed ID: 25284134 [Abstract] [Full Text] [Related]
16. Conventional treatment of Crohn's disease: objectives and outcomes. Rutgeerts PJ. Inflamm Bowel Dis; 2001 May 21; 7 Suppl 1():S2-8. PubMed ID: 11380039 [Abstract] [Full Text] [Related]
17. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Treton X, Bouhnik Y, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Cosnes J, Lemann M, Groupe D'Etude Thérapeutique Des Affections Inflammatoires Du Tube Digestif (GETAID). Clin Gastroenterol Hepatol; 2009 Jan 21; 7(1):80-5. PubMed ID: 18849016 [Abstract] [Full Text] [Related]
18. Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance. Park MS, Kim DH, Kim DH, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Dig Dis Sci; 2015 Jan 21; 60(1):195-204. PubMed ID: 25239495 [Abstract] [Full Text] [Related]
19. Use of 6-mercaptopurine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: pro. Hyams JS. Inflamm Bowel Dis; 2005 Feb 21; 11(2):197-9. PubMed ID: 15677914 [No Abstract] [Full Text] [Related]
20. Efficacy and safety of azathioprine maintenance therapy in a group of Crohn's disease patients in China. Zheng JJ, Chu XQ, Shi XH, Zhou CL, Seng BW. J Dig Dis; 2008 May 21; 9(2):84-8. PubMed ID: 18419641 [Abstract] [Full Text] [Related] Page: [Next] [New Search]